Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a 'Buy' rating on Nurix Therapeutics (NASDAQ:NRIX) and maintained a price target of $31.
September 07, 2023 | 3:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a 'Buy' rating on Nurix Therapeutics and maintained a price target of $31.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $31 price target indicates a positive outlook for Nurix Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100